Close



Feb 12, 2024 08:32AM
Feb 12, 2024 08:30AM
Aug 8, 2023 04:01PM
Jan 3, 2023 08:31AM
Jan 3, 2023 08:30AM
Dec 6, 2022 03:00PM
Oct 11, 2022 08:31AM Gilead Sciences (GILD) Announces U.S. FDA Accepts for Priority Review sBLA for Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer
Oct 11, 2022 08:30AM
Aug 22, 2022 05:42AM
Aug 22, 2022 01:00AM
Aug 2, 2022 04:01PM
Jun 27, 2022 04:30PM
Jun 27, 2022 04:30PM
Feb 1, 2022 04:02PM Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
Dec 11, 2021 08:30AM
Oct 28, 2021 04:02PM
Sep 20, 2021 08:30AM
Jul 29, 2021 04:01PM
Jun 4, 2021 02:30PM
Jun 4, 2021 02:30PM
Dec 5, 2020 12:30PM Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study
Nov 5, 2020 09:00AM
Feb 10, 2020 08:33AM
Feb 10, 2020 08:30AM
Jan 9, 2018 01:58PM
Nov 13, 2017 05:21AM
Nov 10, 2017 02:41PM
Oct 26, 2017 04:01PM Gilead Sciences Announces Third Quarter 2017 Financial Results
Oct 19, 2017 07:27AM
Oct 4, 2017 08:02AM
Oct 4, 2017 08:00AM
Oct 3, 2017 08:45AM
Oct 3, 2017 08:01AM
Oct 3, 2017 08:00AM
Sep 26, 2017 08:31AM Gilead Sciences (GILD), Kite Pharma (KITE) Announce Expiration of HSR Waiting Period
Sep 26, 2017 08:30AM
Aug 28, 2017 07:01AM
Aug 28, 2017 07:00AM
Aug 10, 2017 04:01PM
Aug 10, 2017 04:01PM
Jul 27, 2017 07:00AM
Jun 23, 2017 07:36AM Gilead Sciences (GILD) Announces European CHMP Adopts Positive Opinion for Vosevi for Treatment of All Chronic Hepatitis C Genotypes
Jun 23, 2017 07:35AM
May 2, 2017 04:01PM
Jun 24, 2016 11:13AM
May 27, 2016 07:30AM
May 27, 2016 07:25AM
Apr 15, 2016 06:22AM
Apr 15, 2016 04:30AM Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Apr 8, 2016 07:02AM

12,335 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All